Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label "stelara r adult patients with moderate to severe plaque psoriasis ps 1 1 active psoriatic arthritis psa 1 2 moderately to severely active crohn s disease cd failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed a tumor necrosis factor tnf blocker or failed or were intolerant to treatment with one or more tnf blockers 1 3 adolescent patients 12 years or older with moderate to severe plaque psoriasis 1 1 stelara r stelara r r stelara r failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor tnf blocker or failed or were intolerant to treatment with one or more tnf blockers" assertion.
- association label "simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 1 1 active psoriatic arthritis psa alone or in combination with methotrexate 1 2 active ankylosing spondylitis as 1 3 moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 1 4 inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders simponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis simponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritis simponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6 mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 14 4" assertion.
- association label "simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 1 1 active psoriatic arthritis psa alone or in combination with methotrexate 1 2 active ankylosing spondylitis as 1 3 moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 1 4 inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders simponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis simponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritis simponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6 mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 14 4" assertion.
- association label "cimzia is a tumor necrosis factor tnf blocker indicated for reducing signs and symptoms of crohn s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 1 treatment of adults with moderately to severely active rheumatoid arthritis 1 2 treatment of adult patients with active psoriatic arthritis 1 3 treatment of adults with active ankylosing spondylitis 1 4 treatment of adults with active non radiographic axial spondyloarthritis with objective signs of inflammation 1 5 treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy 1 6 cimzia is indicated for reducing signs and symptoms of crohn s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy cimzia is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis ra cimzia is indicated for the treatment of adult patients with active psoriatic arthritis psa cimzia is indicated for the treatment of adults with active ankylosing spondylitis as see clinical studies 14 4 cimzia is indicated for the treatment of adults with active non radiographic axial spondyloarthritis nr axspa with objective signs of inflammation see clinical studies 14 5 cimzia is indicated for the treatment of adults with moderate to severe plaque psoriasis pso who are candidates for systemic therapy or phototherapy see clinical studies 14 6" assertion.
- association label "tysabri is an integrin receptor antagonist indicated for treatment of multiple sclerosis ms tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri 1 1 5 1 crohn s disease cd tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohn s disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnf a 1 2 important limitations in cd tysabri should not be used in combination with immunosuppressants or inhibitors of tnf a 1 2 tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri see warnings and precautions 5 1 tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohn s disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnf a tysabri should not be used in combination with immunosuppressants e g 6 mercaptopurine azathioprine cyclosporine or methotrexate or inhibitors of tnf a see warnings and precautions 5 1" assertion.
- association label "lucentis is indicated for the treatment of patients with lucentis a vascular endothelial growth factor vegf inhibitor is indicated for the treatment of patients with neovascular wet age related macular degeneration amd 1 1 macular edema following retinal vein occlusion rvo 1 2 diabetic macular edema dme 1 3 diabetic retinopathy dr 1 4 myopic choroidal neovascularization mcnv 1 5" assertion.
- association label "renflexis is a tumor necrosis factor tnf blocker indicated for crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 1 reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease 1 1 pediatric crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 2 ulcerative colitis reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 3 pediatric ulcerative colitis reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 4 rheumatoid arthritis in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active disease 1 5 ankylosing spondylitis reducing signs and symptoms in patients with active disease 1 6 psoriatic arthritis reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function 1 7 plaque psoriasis treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate 1 8 renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn s disease renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis in combination with methotrexate is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis renflexis is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis renflexis is indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis renflexis is indicated for the treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate renflexis should only be administered to patients who will be closely monitored and have regular follow up visits with a physician see boxed warnings warnings and precautions 5" assertion.
- association label "rituxan rituximab is a cd2 directed cytolytic antibody indicated for the treatment of adult patients with non hodgkin s lymphoma nhl 1 1 relapsed or refractory low grade or follicular cd2 positive b cell nhl as a single agent previously untreated follicular cd2 positive b cell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single agent maintenance therapy non progressing including stable disease low grade cd2 positive b cell nhl as a single agent after first line cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large b cell cd2 positive nhl in combination with cyclophosphamide doxorubicin vincristine and prednisone chop or other anthracycline based chemotherapy regimens chronic lymphocytic leukemia cll 1 2 previously untreated and previously treated cd2 positive cll in combination with fludarabine and cyclophosphamide fc rheumatoid arthritis ra in combination with methotrexate in adult patients with moderately to severely active ra who have inadequate response to one or more tnf antagonist therapies 1 3 granulomatosis with polyangiitis gpa wegener s granulomatosis and microscopic polyangiitis mpa in adult patients in combination with glucocorticoids 1 4 moderate to severe pemphigus vulgaris pv in adult patients 1 5 rituxan rituximab is indicated for the treatment of adult patients with relapsed or refractory low grade or follicular cd2 positive b cell nhl as a single agent previously untreated follicular cd2 positive b cell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single agent maintenance therapy non progressing including stable disease low grade cd2 positive b cell nhl as a single agent after first line cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large b cell cd2 positive nhl in combination with cyclophosphamide doxorubicin vincristine prednisone chop or other anthracycline based chemotherapy regimens rituxan is indicated in combination with fludarabine and cyclophosphamide fc for the treatment of adult patients with previously untreated and previously treated cd2 positive cll rituxan in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tnf antagonist therapies rituxan in combination with glucocorticoids is indicated for the treatment of adult patients with granulomatosis with polyangiitis gpa wegener s granulomatosis and microscopic polyangiitis mpa rituxan is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris" assertion.
- association label "novolog mix 7 3 is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus important limitations of use in premix insulins such as novolog mix 7 3 the proportions of rapid acting and long acting insulins are fixed and do not allow for basal versus prandial dose adjustments novolog mix 7 3 is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus important limitations of use in premix insulins such as novolog mix 7 3 the proportions of rapid acting and long acting insulins are fixed and do not allow for basal versus prandial dose adjustments 1" assertion.
- association label "gazyva obinutuzumab is a cd2 directed cytolytic antibody and is indicated in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia 1 14 in combination with bendamustine followed by gazyva monotherapy for the treatment of patients with follicular lymphoma who relapsed after or are refractory to a rituximab containing regimen 1 14 in combination with chemotherapy followed by gazyva monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage ii bulky iii or iv follicular lymphoma 1 14 gazyva in combination with chlorambucil is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia see clinical studies 14 1 gazyva in combination with bendamustine followed by gazyva monotherapy is indicated for the treatment of patients with follicular lymphoma who relapsed after or are refractory to a rituximab containing regimen see clinical studies 14 2 gazyva in combination with chemotherapy followed by gazyva monotherapy in patients achieving at least a partial remission is indicated for the treatment of adult patients with previously untreated stage ii bulky iii or iv follicular lymphoma see clinical studies 14 2" assertion.
- association label "rapamune is an mtor inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged 13 years receiving renal transplants 1 1 1 1 1 1 1 2 14 3 rapamune is an mtor inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis 1 3 rapamune sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants in patients at low to moderate immunologic risk see dosage and administration 2 2 in patients at high immunologic risk see dosage and administration 2 3 clinical studies 14 3 cyclosporine withdrawal has not been studied in patients with banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal those who are dialysis dependent those with serum creatinine 4 5 mg dl black patients patients of multi organ transplants secondary transplants or those with high levels of panel reactive antibodies see clinical studies 14 2 in patients at high immunologic risk see clinical studies 14 3 in pediatric patients see adverse reactions 6 5 clinical studies 14 6 the safety and efficacy of de novo see warnings and precautions 5 12 the safety and efficacy of conversion from calcineurin inhibitors to rapamune see clinical studies 14 4 rapamune sirolimus is indicated for the treatment of patients with lymphangioleiomyomatosis lam" assertion.
- association label "vraylar r is indicated for the treatment of schizophrenia in adults see clinical studies 14 1 acute treatment of manic or mixed episodes associated with bipolar i disorder in adults see clinical studies 14 2 vraylar is an atypical antipsychotic indicated for the treatment of schizophrenia in adults 1 acute treatment of manic or mixed episodes associated with bipolar i disorder in adults 1" assertion.
- association label "northera is indicated for the treatment of orthostatic dizziness lightheadedness or the feeling that you are about to black out in adult patients with symptomatic neurogenic orthostatic hypotension noh caused by primary autonomic failure parkinson s disease pd multiple system atrophy and pure autonomic failure dopamine beta hydroxylase deficiency and non diabetic autonomic neuropathy effectiveness beyond 2 weeks of treatment has not been established the continued effectiveness of northera should be assessed periodically northera is indicated for the treatment of orthostatic dizziness lightheadedness or the feeling that you are about to black out in adult patients with symptomatic neurogenic orthostatic hypotension noh caused by primary autonomic failure parkinson s disease pd multiple system atrophy and pure autonomic failure dopamine beta hydroxylase deficiency and non diabetic autonomic neuropathy effectiveness beyond 2 weeks of treatment has not been established the continued effectiveness of northera should be assessed periodically 1" assertion.
- association label "yondelis r see clinical studies 14 yondelis is an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline containing regimen 1" assertion.
- association label "panhematin is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women after initial carbohydrate therapy is known or suspected to be inadequate limitations of use see dosage and administration 2 1 panhematin is a hemin for injection indicated for amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women after initial carbohydrate therapy is known or suspected to be inadequate 1 limitations of use 1 1" assertion.
- association label "cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases 1 1 minimal change nephrotic syndrome in pediatric patients 1 2 limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established cyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkin s disease lymphocytic lymphoma nodular or diffuse mixed cell type lymphoma histiocytic lymphoma burkitt s lymphoma multiple myeloma leukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stem cell leukemia cyclophosphamide for injection given during remission is effective in prolonging its duration mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma carcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugs cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established" assertion.
- association label "cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases 1 1 minimal change nephrotic syndrome in pediatric patients 1 2 limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established cyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkin s disease lymphocytic lymphoma nodular or diffuse mixed cell type lymphoma histiocytic lymphoma burkitt s lymphoma multiple myeloma leukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stem cell leukemia cyclophosphamide for injection given during remission is effective in prolonging its duration mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma carcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugs cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established" assertion.
- association label "cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases 1 1 minimal change nephrotic syndrome in pediatric patients 1 2 limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established cyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkin s disease lymphocytic lymphoma nodular or diffuse mixed cell type lymphoma histiocytic lymphoma burkitt s lymphoma multiple myeloma leukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stem cell leukemia cyclophosphamide for injection given during remission is effective in prolonging its duration mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma carcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugs cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established" assertion.
- association label "enalapril maleate tablets usp are indicated for the treatment of hypertension enalapril maleate tablets usp are effective alone or in combination with other antihypertensive agents especially thiazide type diuretics the blood pressure lowering effects of enalapril maleate tablets usp and thiazides are approximately additive enalapril maleate tablets usp are indicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalis in these patients enalapril maleate tablets usp improve symptoms increase survival and decrease the frequency of hospitalization see clinical pharmacology heart failure mortality trials in clinically stable asymptomatic patients with left ventricular dysfunction ejection fraction 35 percent enalapril maleate tablets usp decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure see clinical pharmacology heart failure mortality trials in using enalapril maleate tablets usp consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease and that available data are insufficient to show that enalapril maleate tablets usp do not have a similar risk see warnings in considering use of enalapril maleate tablets usp it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non blacks see warnings anaphylactoid and possibly related reactions head and neck angioedema" assertion.
- association label "ilaris is an interleukin 1b blocker indicated for the treatment of periodic fever syndromes cryopyrin associated periodi c syndromes caps familial cold autoinflammatory syndrome fcas 1 1 muckle wells syndrome mws 1 1 tumor necrosis factor receptor associated periodic syndrome traps 1 1 hyperimmunoglobulin d syndrome hids mevalonate kinase deficiency mkd 1 1 familial mediterranean fever fmf 1 1 active systemic juvenile idiopathic arthritis sjia 1 2 ilaris r cryopyrin associated periodic syndromes caps ilaris is indicated for the treatment of cryopyrin associated periodic syndromes caps in adults and children 4 years of age and older including familial cold autoinflammatory syndrome fcas muckle wells syndrome mws tumor necrosis factor receptor tnf associated periodic syndrome traps ilaris is indicated for the treatment of tumor necrosis factor tnf receptor associated periodic syndrome traps in adult and pediatric patients hyperimmunoglobulin d syndrome hids mevalonate kinase deficiency mkd ilaris is indicated for the treatment of hyperimmunoglobulin d hyper igd syndrome hids mevalonate kinase deficiency mkd in adult and pediatric patients familial mediterranean fever fmf ilaris is indicated for the treatment of familial mediterranean fever fmf in adult and pediatric patients ilaris is indicated for the treatment of active systemic juvenile idiopathic arthritis sjia in patients aged 2 years and older" assertion.
- association label "nuzyra is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms 1 community acquired bacterial pneumonia cabp 1 1 acute bacterial skin and skin structure infections absssi 1 2 to reduce the development of drug resistant bacteria and maintain the effectiveness of nuzyra and other antibacterial drugs nuzyra should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria 1 3 nuzyra is indicated for the treatment of adult patients with community acquired bacterial pneumonia cabp caused by the following susceptible microorganisms streptococcus pneumoniae staphylococcus aureus haemophilus influenzae haemophilus parainfluenzae klebsiella pneumoniae legionella pneumophila mycoplasma pneumoniae and chlamydophila pneumoniae nuzyra is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections absssi caused by the following susceptible microorganisms staphylococcus aureus staphylococcus lugdunensis streptococcus pyogenes streptococcus anginosus s anginosus s intermedius s constellatus enterococcus faecalis enterobacter cloacae klebsiella pneumoniae to reduce the development of drug resistant bacteria and maintain the effectiveness of nuzyra and other antibacterial drugs nuzyra should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy" assertion.
- pharmacogenomics_guided_clopidogrel_therapy label "pharmacogenomics guided clopidogrel therapy" assertion.
- spi label "Pharmacogenomics-guided clopidogrel strategy represents a cost-effective treatment for patients undergoing PCI" assertion.
- spi label "Every thing of type adherence to FAIR Guiding Principles that is in the context of a thing of type dataset can have a relation of type enables to a thing of type automated discovery that is in the same context (i.e. the same dataset)." assertion.
- sdata.2016.18 label "The FAIR Guiding Principles for scientific data management and stewardship" assertion.
- semantic-triples-generated-from-XML-files label "semantic triples generated from XML files" assertion.
- spi label "The OpenBiodiv knowledge graph contains semantic triples extracted from biodiversity literature" assertion.
- spi label "Licenses with a non-commercial clause generally inhibit re-use of biodiversity data." assertion.
- obesity-wih-metabolic-abnormality label "obesity with metabolic abnormality" assertion.
- spi label "Obesity when accompanied by metabolic abnormality is closely associated with knee osteoarthritis." assertion.
- obesity-wih-metabolic-abnormality label "obesity wih metabolic abnormality" assertion.
- C0026565 label "death rate" provenance.
- C0026565 label "death rate" provenance.
- C0026565 label "death rate" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality" provenance.
- C0026565 label "mortality rates" provenance.
- C0026565 label "mortality rates" provenance.
- C0026565 label "mortality rates" provenance.
- C0026565 label "mortality rates" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.